Table 2.
Factors Associated with Treatments Given (Chemotherapy, Radiotherapy, or Chemotherapy and Radiotherapy) in Patients with Localized Synovial Sarcoma, 2000–2018. Associations Reported as Odds Ratios with Respective 95% Confidence Intervals
| Characteristics |
Chemotherapy |
Radiotherapy |
Chemotherapy and radiotherapy |
|||
|---|---|---|---|---|---|---|
| AYA |
Adults |
AYA |
Adults |
AYA |
Adults |
|
| Total | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) |
| Age | ||||||
| 15–18 | Reference | Reference | Reference | |||
| 19–21 | 0.68 (0.26–1.74) | 0.93 (0.37–2.34) | 0.85 (0.33–2.17) | |||
| 22–30 | 0.72 (0.34–1.51) | 1.17 (0.56–2.44) | 0.94 (0.44–2.00) | |||
| 31–39 | 0.67 (0.32–1.38) | 0.92 (0.45–1.88) | 0.77 (0.36–1.63) | |||
| 40–65 | Reference | Reference | Reference | |||
| >65 | 0.11 (0.03–0.43) | 0.79 (0.34–1.85) | 0.07 (0.01–0.55) | |||
| Sex | ||||||
| Female | Reference | Reference | Reference | Reference | Reference | Reference |
| Male | 0.71 (0.42–1.21) | 0.64 (0.34–1.18) | 0.9 (0.54–1.51) | 1.01 (0.57–1.77) | 0.79 (0.46–1.35) | 0.67 (0.34–1.31) |
| Health insurance | ||||||
| Private | Reference | Reference | Reference | Reference | Reference | Reference |
| Public/uninsured | 1.24 (0.64–2.43) | 0.44 (0.20–0.95) | 1.05 (0.54–2.06) | 0.43 (0.22–0.86) | 1.08 (0.55–2.11) | 0.32 (0.13–0.79) |
| Unknown | 0.81 (0.19–3.39) | 0.73 (0.14–3.88) | 0.42 (0.11–1.62) | 0.36 (0.09–1.44) | 0.58 (0.14–2.50) | 0.18 (0.02–1.71) |
| Race/ethnicity | ||||||
| NH White | Reference | Reference | Reference | Reference | Reference | Reference |
| Black | 2.21 (0.69–7.10) | 1.64 (0.41–6.62) | 0.5 (0.16–1.55) | 1.97 (0.56–6.98) | 1.26 (0.37–4.32) | 2.36 (0.51–10.81) |
| Hispanic | 1.36 (0.70–2.64) | 1.73 (0.83–3.61) | 1.21 (0.63–2.32) | 1.52 (0.76–3.05) | 1.52 (0.78–2.97) | 2.04 (0.91–4.57) |
| Asian/PI | 1.11 (0.44–2.75) | 1.01 (0.37–2.77) | 0.95 (0.38–2.34) | 1.81 (0.67–4.93) | 0.65 (0.24–1.76) | 1.74 (0.59–5.14) |
| Neighborhood socioeconomic status | ||||||
| Low | Reference | Reference | Reference | Reference | Reference | Reference |
| Medium | 0.61 (0.31–1.18) | 1.55 (0.68–3.56) | 1.83 (0.96–3.49) | 1.21 (0.56–2.64) | 1.2 (0.62–2.33) | 2.18 (0.88–5.40) |
| High | 0.83 (0.39–1.77) | 3.20 (1.40–7.31) | 1.71 (0.79–3.68) | 1.36 (0.65–2.87) | 1.31 (0.60–2.89) | 3.03 (1.24–7.41) |
| Tumor size | ||||||
| 0–5 cm | Reference | Reference | Reference | Reference | Reference | Reference |
| 5.1–10 cm | 4.83 (2.66–8.79) | 2.52 (1.22–5.22) | 2.08 (1.14–3.80) | 1.4 (0.71–2.77) | 5.11 (2.76–9.45) | 3.06 (1.39–6.72) |
| >10 cm | 6.95 (2.64–18.25) | 5.21 (2.28–11.92) | 1.13 (0.47–2.72) | 1.5 (0.69–3.28) | 2.29 (0.94–5.55) | 5.98 (2.45–14.56) |
| Unknown | 1.54 (0.66–3.61) | 1.16 (0.33–4.04) | 0.47 (0.21–1.08) | 0.22 (0.07–0.67) | 1.72 (0.67–4.43) | 0.54 (0.10–2.96) |
| Primary site | ||||||
| Extremity | Reference | Reference | Reference | Reference | Reference | Reference |
| Body wall | 0.37 (0.17–0.82) | 1.06 (0.47–2.39) | 0.48 (0.24–0.99) | 0.58 (0.27–1.25) | 0.26 (0.11–0.62) | 0.7 (0.28–1.73) |
| Head/neck | 0.99 (0.35–2.79) | 0.32 (0.06–1.71) | 4.85 (1.25–18.80) | 3.63 (0.90–14.58) | 1.66 (0.56–4.89) | 0.62 (0.11–3.53) |
| Visceral | 1.76 (0.33–9.35) | 0.48 (0.13–1.71) | 0.08 (0.01–0.69) | 0.08 (0.02–0.31) | 0.17 (0.02–1.52) | 0.12 (0.02–0.74) |
| Comorbidities | ||||||
| No | Reference | Reference | Reference | Reference | Reference | Reference |
| Yes | 0.84 (0.27–2.56) | 1.46 (0.66–3.21) | 5.89 (1.18–29.32) | 1.08 (0.51–2.27) | 1.17 (0.40–3.44) | 2.32 (0.98–5.51) |
| Unknown | 0.4 (0.22–0.72) | 0.75 (0.34–1.63) | 0.85 (0.49–1.48) | 0.86 (0.42–1.75) | 0.53 (0.29–0.99) | 0.87 (0.36–2.10) |
| Distance to SCC | ||||||
| 0–10 miles | Reference | Reference | Reference | Reference | Reference | Reference |
| 11–20 miles | 0.8 (0.39–1.62) | 1.2 (0.55–2.59) | 1.43 (0.70–2.89) | 0.8 (0.39–1.62) | 1.12 (0.55–2.27) | 1.13 (0.47–2.71) |
| 21–30 miles | 0.94 (0.37–2.43) | 0.96 (0.33–2.83) | 0.72 (0.27–1.90) | 1.88 (0.63–5.57) | 0.9 (0.32–2.51) | 1.46 (0.45–4.73) |
| 31–40 miles | 0.84 (0.20–3.57) | 1.03 (0.22–4.84) | 2.74 (0.64–11.76) | 7.87 (0.79–78.81) | 0.84 (0.24–2.99) | 2.3 (0.44–11.93) |
| >40 miles | 0.87 (0.41–1.86) | 0.8 (0.32–1.97) | 0.58 (0.28–1.16) | 1.13 (0.49–2.60) | 0.59 (0.27–1.28) | 1.32 (0.51–3.45) |
| Initial cancer care at an SCC | ||||||
| None | Reference | Reference | Reference | Reference | Reference | Reference |
| All | 2.26 (1.16–4.41) | 0.97 (0.38–2.48) | 0.88 (0.47–1.66) | 0.78 (0.34–1.80) | 1.31 (0.64–2.68) | 1.29 (0.46–3.65) |
| Some | 2.74 (1.48–5.07) | 3.57 (1.83–6.98) | 1.99 (1.07–3.70) | 1.48 (0.78–2.81) | 3.38 (1.77–6.46) | 3.09 (1.48–6.41) |
Bold values are statistically significant.
AYA, adolescents and young adults; CI, confidence interval; NH, non-Hispanic; OR, odds ratio; PI, Pacific Islander; SCC, Specialized Cancer Center.